aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-10 17:51Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against aTyr, with a deadline of December 9, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [6]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant reduction in mean daily oral corticosteroid (OCS) dose compared to placebo, with only 52.6% of patients achieving complete steroid withdrawal [7]. Group 3: Stock Performance Impact - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].